Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis - Kurasawa, Kazuhiro; Arai, Satoko; Namiki, Yumeko; Tanaka, Ayae; Takamura, Yuta; Owada, Takayoshi; Arima, Masafumi; Maezawa, Reika (Rheumatology (Oxford, England), 2018)
Keywords: Adult; Aged; Dermatomyositis - blood; Dermatomyositis - complications; Dermatomyositis - immunology; Drug Therapy, Combination; Female; Ferritins - blood; Glucocorticoids - administration & dosage; Humans; Interferon-Induced Helicase, IFIH1 - blood; Lung - pathology; Lung Diseases, Interstitial - drug therapy; Lung Diseases, Interstitial - immunology; Lung Diseases, Interstitial - pathology; Male; Middle Aged; Piperidines - therapeutic use; Prognosis; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Pyrroles - therapeutic use; Survival Rate; Treatment Outcome; immunosuppressive therapy; dermatomyositis; prognostic factors; interstitial lung disease; anti-MDA5 antibody; tofacitinib